608 related articles for article (PubMed ID: 16488571)
1. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
[TBL] [Abstract][Full Text] [Related]
2. Vibrational bone characteristics versus bone density for the assessment of osteoporosis in ovariectomized rats.
Anastassopoulos G; Panteliou S; Christopoulou G; Stavropoulou A; Panagiotopoulos E; Lyritis G; Khaldi L; Varakis J; Karamanos N
J Med Eng Technol; 2010 Jan; 34(1):35-42. PubMed ID: 19995148
[TBL] [Abstract][Full Text] [Related]
3. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
[TBL] [Abstract][Full Text] [Related]
4. Alteration in serum leptin correlates with alterations in serum N-telopeptide of collagen type I and serum osteocalcin during the progression of osteoporosis in ovariectomized rats.
Stavropoulou A; Christopoulou GE; Anastassopoulos G; Panteliou SD; Lyritis GP; Spiliotis BE; Karamanos NK; Panagiotopoulos E; Lambiris E
Clin Chem Lab Med; 2005; 43(12):1359-65. PubMed ID: 16309373
[TBL] [Abstract][Full Text] [Related]
5. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
6. Onion decreases the ovariectomy-induced osteopenia in young adult rats.
Huang TH; Mühlbauer RC; Tang CH; Chen HI; Chang GL; Huang YW; Lai YT; Lin HS; Yang WT; Yang RS
Bone; 2008 Jun; 42(6):1154-63. PubMed ID: 18387868
[TBL] [Abstract][Full Text] [Related]
7. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.
Gasser JA; Ingold P; Venturiere A; Shen V; Green JR
J Bone Miner Res; 2008 Apr; 23(4):544-51. PubMed ID: 18072878
[TBL] [Abstract][Full Text] [Related]
8. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
9. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
10. A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat.
Cho DC; Kim KT; Jeon Y; Sung JK
Acta Neurochir (Wien); 2012 Dec; 154(12):2215-23. PubMed ID: 23053289
[TBL] [Abstract][Full Text] [Related]
11. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
[TBL] [Abstract][Full Text] [Related]
12. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A
Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319
[TBL] [Abstract][Full Text] [Related]
13. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
[TBL] [Abstract][Full Text] [Related]
14. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
15. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Morko J; Rasi S; Risteli J; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):155-61. PubMed ID: 18219436
[TBL] [Abstract][Full Text] [Related]
16. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
Pivonello R; Faggiano A; Di Somma C; Klain M; Filippella M; Salvatore M; Lombardi G; Colao A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
[TBL] [Abstract][Full Text] [Related]
17. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
[TBL] [Abstract][Full Text] [Related]
18. Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats.
Elwakkad AS; El Elshamy KA; Sibaii H
Epilepsy Res; 2008 Jul; 80(1):47-56. PubMed ID: 18455911
[TBL] [Abstract][Full Text] [Related]
19. Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat.
Wezeman FH; Emanuele MA; Moskal SF; Steiner J; Lapaglia N
J Bone Miner Res; 2000 Oct; 15(10):2033-41. PubMed ID: 11028458
[TBL] [Abstract][Full Text] [Related]
20. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
